998 related articles for article (PubMed ID: 12748257)
21. Immunophenotype and possible origin of nevi with phenotypical heterogeneity.
Winnepenninckx V; van den Oord JJ
Arch Dermatol Res; 2004 Jul; 296(2):49-53. PubMed ID: 15141316
[TBL] [Abstract][Full Text] [Related]
22. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
23. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
[TBL] [Abstract][Full Text] [Related]
24. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
25. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
26. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.
Nonaka D; Chiriboga L; Rubin BP
J Cutan Pathol; 2008 Nov; 35(11):1014-9. PubMed ID: 18547346
[TBL] [Abstract][Full Text] [Related]
28. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
29. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
30. "Triggered trap": nevoid malignant melanoma.
McNutt NS
Semin Diagn Pathol; 1998 Aug; 15(3):203-9. PubMed ID: 9711670
[TBL] [Abstract][Full Text] [Related]
31. Spitz nevi: In vivo confocal microscopic features, dermatoscopic aspects, histopathologic correlates, and diagnostic significance.
Pellacani G; Longo C; Ferrara G; Cesinaro AM; Bassoli S; Guitera P; Menzies SW; Seidenari S
J Am Acad Dermatol; 2009 Feb; 60(2):236-47. PubMed ID: 19091443
[TBL] [Abstract][Full Text] [Related]
32. Rosette-like structures in the spectrum of spitzoid tumors.
Arps DP; Harms PW; Chan MP; Fullen DR
J Cutan Pathol; 2013 Sep; 40(9):788-95. PubMed ID: 23808731
[TBL] [Abstract][Full Text] [Related]
33. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
34. Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays.
Fullen DR; Garrisi AJ; Sanders D; Thomas D
J Cutan Pathol; 2008 Nov; 35 Suppl 2():28-34. PubMed ID: 18201235
[TBL] [Abstract][Full Text] [Related]
35. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
36. Silhouette symmetry: an unsupportable histologic criterion for distinguishing Spitz nevi and compound nevi from malignant melanoma.
Okun MR
Arch Pathol Lab Med; 1997 Jan; 121(1):48-53. PubMed ID: 9111092
[TBL] [Abstract][Full Text] [Related]
37. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
38. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
39. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics.
Barnhill RL
Clin Plast Surg; 2000 Jul; 27(3):331-60, viii. PubMed ID: 10941557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
